|
gptkbp:instance_of
|
gptkb:Skin
|
|
gptkbp:administered_by
|
inhalation
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:class
|
gptkb:Android
anticholinergic
long-acting beta agonist
|
|
gptkbp:clinical_trial
|
gptkb:TRIBUTE_study
Phase III
REACH study
PIVOTAL study
|
|
gptkbp:clinical_use
|
COPD management
long-term control of asthma
|
|
gptkbp:contains
|
gptkb:glycopyrrolate
gptkb:budesonide
gptkb:formoterol
|
|
gptkbp:contraindication
|
hypersensitivity to components
|
|
gptkbp:dosage_form
|
gptkb:Spider-Man
|
|
gptkbp:form
|
aerosol
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trixeo Aerosphere
|
|
gptkbp:indication
|
maintenance treatment
|
|
gptkbp:ingredients
|
gptkb:glycopyrrolate
gptkb:budesonide
gptkb:formoterol_fumarate
|
|
gptkbp:interacts_with
|
diuretics
beta-blockers
CYP3 A4 inhibitors
|
|
gptkbp:label
|
patient information leaflet
black box warning
prescribing information
|
|
gptkbp:manufacturer
|
gptkb:Astra_Zeneca
|
|
gptkbp:marketed_as
|
gptkb:2021
|
|
gptkbp:packaging
|
pressurized canister
|
|
gptkbp:patient_population
|
adults
children over 12
|
|
gptkbp:previous_name
|
gptkb:budesonide/formoterol/glycopyrrolate
|
|
gptkbp:price
|
varies by insurance
|
|
gptkbp:route_of_administration
|
inhalation
|
|
gptkbp:safety
|
monitor for adrenal insufficiency
not recommended for acute attacks
potential for cardiovascular effects
risk of pneumonia
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
cough
thrush
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
gptkb:asthma
chronic obstructive pulmonary disease
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca
|
|
gptkbp:bfsLayer
|
4
|